title: Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?
authors.forename: Johannes
authors.initials: J
authors.lastname: Rieger
authors.forename: Oliver
authors.initials: O
authors.lastname: Bähr
authors.forename: Michael W
authors.initials: MW
authors.lastname: Ronellenfitsch
authors.forename: Joachim
authors.initials: J
authors.lastname: Steinbach
authors.forename: Elke
authors.initials: E
authors.lastname: Hattingen
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015687:Cell Hypoxia; D038524:Diffusion Magnetic Resonance Imaging; D018450:Disease Progression; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000473:pathology*; D011237:Predictive Value of Tests; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab